Key Takeaways
Opus Genetics, Inc. (Nasdaq: IRD) reported first-quarter financials that missed analyst estimates on revenue and earnings, but the company’s shares rose after it secured a new financing deal extending its operational runway into 2029.
“With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what’s possible for patients with inherited retinal diseases,” George Magrath, M.D., Chief Executive Officer of Opus Genetics, said in a statement.
For the quarter ended March 31, Opus reported a net loss of $65.5 million, or $0.75 per share, a significant miss compared to the Zacks Consensus Estimate of a $0.16 loss per share. Revenue of $2.2 million fell short of an estimated $2.85 million and declined from $4.4 million in the same period last year.
The stock gained 2.61% in trading following the announcement, as investors focused on a strategic financing agreement with Oberland Capital Management. The deal includes $35 million in senior secured notes and a $5 million equity investment, boosting Opus’s cash position to approximately $90 million. The company stated these resources are expected to fund operations into 2029. The larger net loss was primarily driven by a non-cash expense related to the fair value change in warrant liabilities, according to the company's press release.
Opus is advancing multiple gene therapies for inherited retinal diseases. The company expects to announce topline data from Cohort 1 of its Phase 1/2 trial for OPGx-BEST1 in September 2026. Its OPGx-LCA5 program was accepted into the FDA’s Rare Disease Evidence Principles (RDEP) program, with a pivotal Phase 3 trial expected to begin dosing in the fourth quarter of 2026.
The results show that for a clinical-stage biotech like Opus, investors are prioritizing pipeline progress and financial stability over near-term profitability. The extended cash runway allows the company to pursue several clinical milestones without imminent financing pressure. Investors will now watch for the OPGx-BEST1 topline data in September as the next major catalyst.
This article is for informational purposes only and does not constitute investment advice.
